PhoreMost Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PhoreMost Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12354
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PhoreMost Ltd (PhoreMost) is a drug discovery company that develops drugs for the treatment of cancer. The company’s lead drug discovery program is based on a novel target, which tackles the undruggable cancer gene KRAS that affects various types of cancer. It develops Site-Seeker, a platform that systematically unmasks druggable sites in the human genome and links them to useful therapeutic functions in a live-cell context. PhoreMost’s Site Seeker platform differs from other genome-based target screening technologies. The company also provides drug discovery services to a network of co-invested academic and industrial collaboration partners. PhoreMost is headquartered in Cambridge, the UK.

PhoreMost Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PhoreMost Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
PhoreMost Raises USD15 Million in Series A Venture Financing 10
PhoreMost Raises USD3.8 Million in Seed Financing 12
Partnerships 13
PhoreMost Enters into Agreement with o2h discovery 13
PhoreMost Enters into Collaboration Agreement with Plexxikon 14
PhoreMost Enters into Research Agreement with University of Cambridge 15
PhoreMost Enters into Agreement with Wistar Institute 16
Licensing Agreements 17
Phylogica Enters into Licensing Agreement with PhoreMost 17
PhoreMost Ltd – Key Competitors 18
PhoreMost Ltd – Key Employees 19
PhoreMost Ltd – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Government and Public Interest 21
Jun 15, 2017: PhoreMost and Babraham Institute Awarded £0.6M Innovate UK Funding 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
PhoreMost Ltd, Pharmaceuticals & Healthcare, Key Facts 2
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PhoreMost Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PhoreMost Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PhoreMost Raises USD15 Million in Series A Venture Financing 10
PhoreMost Raises USD3.8 Million in Seed Financing 12
PhoreMost Enters into Agreement with o2h discovery 13
PhoreMost Enters into Collaboration Agreement with Plexxikon 14
PhoreMost Enters into Research Agreement with University of Cambridge 15
PhoreMost Enters into Agreement with Wistar Institute 16
Phylogica Enters into Licensing Agreement with PhoreMost 17
PhoreMost Ltd, Key Competitors 18
PhoreMost Ltd, Key Employees 19

List of Figures
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PhoreMost Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[PhoreMost Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Zeta Petroleum Plc (ZTA):企業の財務・戦略的SWOT分析
    Summary Zeta Petroleum Plc (Zeta) is an oil and gas exploration and production company. The company explores, develops and produces natural gas and crude oil. It also owns and operates oil and gas assets such as Bobocu Gas Field, Suceava Concession, Jimbolia Oil Field, and Grivita Nord Oil Field. Ze …
  • Global Investment House KPSC:企業の戦略的SWOT分析
    Global Investment House KPSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Orchid Pharma Ltd (ORCHIDPHAR):企業の財務・戦略的SWOT分析
    Summary Orchid Pharma Ltd (Orchid), formerly Orchid Chemicals & Pharmaceuticals Ltd is a pharmaceutical company that develops and manufactures pharmaceutical solutions such as formulations and API products. The company offers formulations such as cardiovascular products, neuropsychiatry products, an …
  • Karachaganak Petroleum Operating BV:企業の戦略的SWOT分析
    Karachaganak Petroleum Operating BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • SeaBird Exploration PLC (SBX):企業の財務・戦略的SWOT分析
    Summary SeaBird Exploration PLC (SeaBird) operates as an oil and gas company that offers marine seismic data services. The company’s services include 2D seismic acquisition, 3D and 3D shallow water acquisition and source vessel. Its source vessels offers services such as conventional undershoots, 4d …
  • Pharmascience Inc-製薬・医療分野:企業M&A・提携分析
    Summary Pharmascience Inc (Pharmascience) is a pharmaceutical company that develops, manufactures and markets medicinal products. The company offers generic, prescription, over-the-counter and private label OTC products. It offers drugs in therapeutic areas of anti-inflammatory, cancer, cardiovascul …
  • Quantum Genomics SA (ALQGC):企業の財務・戦略的SWOT分析
    Summary Quantum Genomics SA (Quantum Genomics) is a bio pharmaceutical company which develops novel medicines in the field of cardiovascular diseases. The company develops drugs to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition ( …
  • Endurance International Group Holdings, Inc.:企業のM&A・事業提携・投資動向
    Endurance International Group Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Endurance International Group Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, d …
  • OK Biotech Co Ltd (4155):医療機器:M&Aディール及び事業提携情報
    Summary OK Biotech Co Ltd (OK Biotech) is a medical device manufacturing and distribution company that manufactures and distributes blood glucose monitoring devices and homecare medical products, among others. The company’s blood glucose monitoring devices include blood glucose meter systems, blood …
  • Eurofins Scientific SE (ERF):製薬・医療:M&Aディール及び事業提携情報
    Summary Eurofins Scientific SE (Eurofins) is a life sciences company, which provides a range of analytical testing services to clients in various industries. The company offers food and feed testing, biopharma services, pharma discovery services, genomic pharma services, pharma early development, ph …
  • Volta River Authority:電力:M&Aディール及び事業提携情報
    Summary Volta River Authority (VRA) is a state-owned energy utility that generates, transmits, and distributes electricity. It produces power from solar, hydro, light crude oil, distillate fuel oil, and heavy fuel oil sources. The authority procures energy from Takoradi International Company Ltd; an …
  • AAR Corp:戦略・SWOT・企業財務分析
    AAR Corp - Strategy, SWOT and Corporate Finance Report Summary AAR Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Deluxe Corporation:企業の戦略・SWOT・財務分析
    Deluxe Corporation - Strategy, SWOT and Corporate Finance Report Summary Deluxe Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • NovoCure Ltd (NVCR):企業の財務・戦略的SWOT分析
    NovoCure Ltd (NVCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Getinge AB (GETI B):企業の財務・戦略的SWOT分析
    Getinge AB (GETI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mauna Kea Technologies SAS (MKEA):製薬・医療:M&Aディール及び事業提携情報
    Summary Mauna Kea Technologies SAS (MKT) is an endomicroscopy device manufacturer. The company develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. It provides confocal laser endomicroscopy platform. MKT’s cellvizio is an endomicro …
  • Cocrystal Pharma Inc (COCP):企業の財務・戦略的SWOT分析
    Summary Cocrystal Pharma Inc (Cocrystal Pharma), formerly Biozone Pharmaceuticals Inc, a subsidiary of MusclePharm Corp, is a clinical stage biotechnology company that discovers and develops novel antiviral therapeutics. The company provides treatments for chronic viral diseases. Its pipeline produc …
  • SONIFI Solutions, Inc:企業の戦略的SWOT分析
    SONIFI Solutions, Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Sagemcom SAS:企業の戦略的SWOT分析
    Sagemcom SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Sandoz Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Sandoz Inc (Sandoz), a division of Novartis AG (Novartis), is a generic pharmaceutical company that develops, manufactures and distributes and sells a range of prescription medicines and protein and biosimilars. The company also provides intermediary products including active pharmaceutical …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆